Selective T Cell Costimulation Blocker [EPC]

2761 reported adverse events

Drugs of this class: BELATACEPT

These side effects are most commonly reported by patients taking drugs of the Selective T Cell Costimulation Blocker [EPC] class:

# Side effect Count
0 OFF LABEL USE 199
1 DEATH 173
2 KIDNEY TRANSPLANT REJECTION 172
3 TRANSPLANT REJECTION 133
4 CYTOMEGALOVIRUS INFECTION 90
5 ACUTE KIDNEY INJURY 83
6 INTENTIONAL PRODUCT USE ISSUE 82
7 SEPSIS 78
8 HOSPITALISATION 77
9 PYREXIA 77
See all common reactions for Selective T Cell Costimulation Blocker [EPC]

Drugs of the Selective T Cell Costimulation Blocker [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 DIFFUSE MESANGIAL SCLEROSIS 3 0.2143
1 GENE MUTATION IDENTIFICATION TEST NEGATIVE 1 0.1667
2 HERPES SIMPLEX MENINGITIS 8 0.1600
3 CYTOMEGALOVIRUS MYOCARDITIS 2 0.1429
4 PYELONEPHRITIS FUNGAL 5 0.1351
5 EPIGLOTTIC ERYTHEMA 1 0.1111
6 CUTANEOUS BLASTOMYCOSIS 2 0.0952
7 REMOVAL OF RENAL TRANSPLANT 4 0.0952
8 DISSEMINATED BLASTOMYCOSIS 3 0.0938
9 BK POLYOMAVIRUS TEST POSITIVE 4 0.0930
See all enriched reactions for Selective T Cell Costimulation Blocker [EPC]